Literature DB >> 23824804

Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.

Missa P Sanou1, Shannon R Roff, Antony Mennella, John W Sleasman, Mobeen H Rathore, Janet K Yamamoto, Jay A Levy.   

Abstract

Anti-human immunodeficiency virus (HIV) cytotoxic T lymphocyte (CTL)-associated epitopes, evolutionarily conserved on both HIV type 1 (HIV-1) and feline immunodeficiency virus (FIV) reverse transcriptases (RT), were identified using gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) and carboxyfluorescein diacetate succinimide ester (CFSE) proliferation assays followed by CTL-associated cytotoxin analysis. The peripheral blood mononuclear cells (PBMC) or T cells from HIV-1-seropositive (HIV(+)) subjects were stimulated with overlapping RT peptide pools. The PBMC from the HIV(+) subjects had more robust IFN-γ responses to the HIV-1 peptide pools than to the FIV peptide pools, except for peptide-pool F3. In contrast, much higher and more frequent CD8(+) T-cell proliferation responses were observed with the FIV peptide pools than with the HIV peptide pools. HIV-1-seronegative subjects had no proliferation or IFN-γ responses to the HIV and FIV peptide pools. A total of 24% (40 of 166) of the IFN-γ responses to HIV pools and 43% (23 of 53) of the CD8(+) T-cell proliferation responses also correlated to responses to their counterpart FIV pools. Thus, more evolutionarily conserved functional epitopes were identified by T-cell proliferation than by IFN-γ responses. In the HIV(+) subjects, peptide-pool F3, but not the HIV H3 counterpart, induced the most IFN-γ and proliferation responses. These reactions to peptide-pool F3 were highly reproducible and persisted over the 1 to 2 years of testing. All five individual peptides and epitopes of peptide-pool F3 induced IFN-γ and/or proliferation responses in addition to inducing CTL-associated cytotoxin responses (perforin, granzyme A, granzyme B). The epitopes inducing polyfunctional T-cell activities were highly conserved among human, simian, feline, and ungulate lentiviruses, which indicated that these epitopes are evolutionarily conserved. These results suggest that FIV peptides could be used in an HIV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824804      PMCID: PMC3754003          DOI: 10.1128/JVI.00359-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

Review 1.  HIV vaccine design: the neutralizing antibody conundrum.

Authors:  Leonidas Stamatatos
Journal:  Curr Opin Immunol       Date:  2012-05-15       Impact factor: 7.486

Review 2.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

Review 3.  Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.

Authors:  Igor M Belyakov; Jeffrey D Ahlers
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 4.  The design and evaluation of HIV-1 vaccines.

Authors:  Kevin O Saunders; Rebecca S Rudicell; Gary J Nabel
Journal:  AIDS       Date:  2012-06-19       Impact factor: 4.177

5.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

6.  Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens.

Authors:  Sampa Santra; Mark Muldoon; Sydeaka Watson; Adam Buzby; Harikrishnan Balachandran; Kevin R Carlson; Linh Mach; Wing-Pui Kong; Krisha McKee; Zhi-Yong Yang; Srinivas S Rao; John R Mascola; Gary J Nabel; Bette T Korber; Norman L Letvin
Journal:  Virology       Date:  2012-04-21       Impact factor: 3.616

7.  Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees.

Authors:  S S Balla-Jhagjhoorsingh; G Koopman; P Mooij; T G Haaksma; V J Teeuwsen; R E Bontrop; J L Heeney
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

8.  HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals.

Authors:  B D Walker; C Flexner; T J Paradis; T C Fuller; M S Hirsch; R T Schooley; B Moss
Journal:  Science       Date:  1988-04-01       Impact factor: 47.728

9.  Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Authors:  Fusheng Li; Adam C Finnefrock; Sheri A Dubey; Bette T M Korber; James Szinger; Suzanne Cole; M Juliana McElrath; John W Shiver; Danilo R Casimiro; Lawrence Corey; Steven G Self
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

10.  HIV-1 Vaccine Trials: Evolving Concepts and Designs.

Authors:  Missa P Sanou; Anne S De Groot; Michael Murphey-Corb; Jay A Levy; Janet K Yamamoto
Journal:  Open AIDS J       Date:  2012-11-30
View more
  6 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.

Authors:  Shannon R Roff; Missa P Sanou; Mobeen H Rathore; Jay A Levy; Janet K Yamamoto
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Major Histocompatibility Complex Class I (FLA-E*01801) Molecular Structure in Domestic Cats Demonstrates Species-Specific Characteristics in Presenting Viral Antigen Peptides.

Authors:  Ruiying Liang; Yaping Sun; Yanjie Liu; Junya Wang; Yanan Wu; Zibin Li; Lizhen Ma; Nan Zhang; Lijie Zhang; Xiaohui Wei; Zehui Qu; Nianzhi Zhang; Chun Xia
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

4.  Conserved HIV Epitopes for an Effective HIV Vaccine.

Authors:  Bikash Sahay; Cuong Q Nguyen; Janet K Yamamoto
Journal:  J Clin Cell Immunol       Date:  2017-08-30

Review 5.  Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.

Authors:  Bikash Sahay; Janet K Yamamoto
Journal:  Viruses       Date:  2018-05-22       Impact factor: 5.048

6.  Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.

Authors:  Bikash Sahay; Alek M Aranyos; Meerambika Mishra; Andrew C McAvoy; Marcus M Martin; Riuyu Pu; Sayaka Shiomitsu; Keijiro Shiomitsu; Michael J Dark; Missa P Sanou; Shannon R Roff; Mobeen H Rathore; Janet K Yamamoto
Journal:  Viruses       Date:  2019-02-03       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.